366a.T
366A.T operates in the healthcare facilities and services industry, focusing on biotechnology, and generates revenue primarily through the development and provision of biotech-related services and products.
Business. 366A.T is a healthcare company operating within the Healthcare Facilities & Services industry, with a primary focus on biotechnology activities. The firm generates revenue through service-based models typical of the healthcare services sector. Specific details regarding its operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without further geographic or segmental breakdown.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
366A.T is a healthcare company operating within the Healthcare Facilities & Services industry, with a primary focus on biotechnology activities. The firm generates revenue through service-based models typical of the healthcare services sector. Specific details regarding its operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without further geographic or segmental breakdown.
366A.T maintains a strong liquidity position, with cash and equivalents amounting to ¥2.79 billion, representing a significant portion of its total assets of ¥5.18 billion. The company's liquidity FPT (free cash flow to total liabilities) is robust, indicating a solid ability to meet short-term obligations. The current ratio of 2.37 further supports this, showing that the company has more than twice the current assets to cover its current liabilities.
Profitability metrics for 366A.T are favorable compared to industry norms. The company's return on equity (ROE) of 22.45% and return on assets (ROA) of 14.98% are well above the typical thresholds for the healthcare sector, indicating efficient use of equity and assets to generate profit. The net income of ¥776.21 million and operating income of ¥1.11 billion also reflect strong operational performance.
Geographically and segment-wise, 366A.T's revenue is concentrated in its core biotechnology operations, with no disclosed diversification into other business lines or regions. This concentration may expose the company to specific market risks, particularly in the biotech sector, which is subject to regulatory and technological changes.
The company's growth trajectory is positive, with a revenue of ¥14.06 billion and a gross profit of ¥2.81 billion. While no specific growth rate is provided, the company's strong cash flow and profitability suggest a stable and potentially growing business. The outlook for the current fiscal year indicates continued performance, supported by the company's strong financial position.
Risk factors for 366A.T are minimal, with low liquidity and dilution risks identified. The company has no immediate filing-based liquidity or dilution flags, and its capital structure is supported by a low debt-to-equity ratio of 0.0, indicating a conservative approach to financing. The absence of long-term debt further reduces financial risk.
Recent events and filings for 366A.T do not indicate any significant changes or risks. The company's financial statements and disclosures are consistent with a stable and well-managed business. No recent major events or regulatory actions have been reported that would impact the company's operations or financial health.
- 366A.T has a strong liquidity position with significant cash reserves and a low debt-to-equity ratio.
- The company's profitability metrics, including ROE and ROA, are well above industry norms.
- Revenue is concentrated in the biotechnology sector, which may pose specific market risks.
- The company's growth trajectory is supported by strong cash flow and profitability.
- Risk factors are minimal, with no immediate liquidity or dilution concerns.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 366A.T Market data — financials · 2026-05-26